

PRODUCT DATA SHEET

Product: Fas Ligand, soluble (human recombinant)

Cat. No.: FL-101 (10 µg)

Page 1 of 2

Synonyms:

APO-1L, soluble; CD95L, soluble; CD178, soluble; TNFSF 6, soluble

Protein:

Recombinant, human sFasL (rhsFasL)

Specificity:

rhsFasL binds to human, mouse and rat Fas (CD95, APO-1).

Species Reactivity:

Human, mouse and rat. Others not tested.

Source:

The extracellular domain of human FasL (sFasL, aa. 103-281) is fused at the N-terminus to a linker peptide (26 aa) and a FLAG[®]-tag. Glycosylation of rhsFasL is similar to natural human FasL. The recombinant protein is produced in HEK 293 cells.

Molecular Weight:

~32 kDa (non-glycosylated), ~35 kDa (glycosylated) (SDS-PAGE)

Format:

Provided as a lyophilized powder. Contains PBS.

Purity:

≥95% purity as determined by SDS-PAGE. Endotoxin content is <0.1 EU/µg purified protein as determined by LAL test.

Reconstitution:

Prepare sterile stock solution by dissolving rhsFasL in 100 µL sterile water (0.1 mg/mL in PBS). Further dilutions should be made with medium containing 5% fetal calf serum.

Storage:

Store at -20°C long term. Once rehydrated it is recommended to prepare appropriate aliquots and store them at -20°C. Avoid repeated freeze/thaw cycles.

Application:

■ Induction of Apoptosis: Recombinant FasL protein induces apoptosis in Fas-sensitive cells (ED₅₀: 50 ng/mL in A20 cells). Optimal concentration varies with cell type and should be determined by testing serial dilutions on cells.

Alone, rhsFasL kills Fas-sensitive cells at a concentration of >10 ng/mL. Use of a secondary enhancing cross-linking antibody reacting with rhsFasL (Cat. No. FL-104) increases the activity of rhsFasL approximately 50-fold.

Note: Results using sFasL may differ from those obtained with agonistic antibodies.





Figure: Inhibition of rhsFasL (Cat. No. FL-101)-mediated lysis. rhsFas:Fc (Fas Ligand Inhibitor, Cat. No. AF-016) exerts its inhibitory activity in a concentration range of 0.5-5 µg/mL in the presence of the enhancer (1 µg/mL).

Method: Mouse A20 B lymphoma cells (50,000 cells in 100 µL DMEM medium containing 5% fetal calf serum) were incubated with 0.2 µg/mL rhsFasL and increasing concentrations of rhFas:Fc fusion protein in the presence and the absence of 1 µg/mL enhancer in a 96 well plate for 16 hours at 37°C. Concentration of rhFas:Fc required to inhibit may vary depending on the cell type studied and on the concentration of rhsFasL used to kill cells. Cell viability was determined using a MTT-based cell proliferation assay kit.

The optimal dilution and incubation times for a specific application should be determined by the researcher.



PRODUCT DATA SHEET

Page 2 of 2

Cat. No.: FL-101 (10 µg)

Limitations:

For *in vitro* research use only. Not for use in diagnostics or in humans.

Warranty:

No warranties, expressed or implied, are made regarding the use of this product. KAMIYA BIOMEDICAL COMPANY is not liable for any damage, personal injury, or economic loss caused by this product.